Aficamten Beneficial for Obstructive Hypertrophic Cardiomyopathy
By Elana Gotkine HealthDay Reporter
THURSDAY, May 16, 2024 -- Treatment with the oral selective cardiac myosin inhibitor aficamten results in significantly greater improvement in peak oxygen uptake compared with placebo among patients with symptomatic obstructive hypertrophic cardiomyopathy (HCM), according to a study published online May 13 in the New England Journal of Medicine to coincide with the European Society of Cardiology Heart Failure 2024, held from May 11 to 14 in Lisbon, Portugal.
Martin S. Maron, M.D., from the Lahey Hospital and Medical Center in Burlington, Massachusetts, and colleagues randomly assigned adults with symptomatic obstructive HCM to receive aficamten or placebo for 24 weeks (142 and 140 patients, respectively) with dose adjustment based on echocardiography results in a phase 3, double-blind trial.
The researchers found that the mean change in peak oxygen uptake was 1.8 and 0.0 mL/kg/min in the aficamten and placebo groups at 24 weeks (least-squares mean between-group difference, 1.7 mL/kg/min). For all 10 secondary end points, results improved significantly with aficamten versus placebo. In the two groups, the incidence of adverse events was similar.
"Among patients with symptomatic obstructive HCM, treatment with aficamten resulted in a significantly greater improvement in peak oxygen uptake than placebo," the authors write.
The study was funded by Cytokinetics, the manufacturer of aficamten.
Abstract/Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted May 2024
Read this next
Guidelines Developed for Management of Hypertrophic Cardiomyopathy
THURSDAY, May 9, 2024 -- In a new clinical guideline issued by the American College of Cardiology and the American Heart Association and published online May 8 in the Journal of...
ACC: Small but Significant Risk for Cardiomyopathy Seen With ADHD Meds
THURSDAY, March 28, 2024 -- Young adults prescribed stimulant medications for attention-deficit/hyperactivity disorder (ADHD) have an increased risk for cardiomyopathy, with the...
Calculator Can Help Tailor Treatment During, After Heart Pump Placement
MONDAY, Feb. 5, 2024 -- The right ventricular failure (RVF) risk score, STOP-RVF calculator, can predict RVF after durable left ventricular assist device (LVAD) placement...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.